Sheet	•	~	•	
heet		Λt		
311661		of		

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No. 10/786,791	
3	Information Disclosure Statement by Applicant		Applicant Zhaoda Zhang et al.		
	(Use several : (37 CFR \$1,08(b))	sheets if necessary)	Filing Date February 25, 2004	Group Art Unit 1616 1618	

POFMARY !			U.S. Paten	t Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE					-	
	AF						
	AG						
	АН						
	AI						
	AJ						
	AK						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or				lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.						
Initial	ID	Document					
(A)	AQ	Copy of office action from related application serial number 10/209,172 mailed 5/5/2004.					
	AR	Copy of response to action from related application serial number 10/209,172 mailed 10/5/04.					
, ,	AS						
	AT						

Formal Ol The	·/		
Examiner Signature	1	Date Considered /	
	1	1 2000 00000000000 /	
	11 / 2/	1 -7.121X	/
		1/12/10	1.7
EYAMINED: Initials situation come	Ida and Denvelles therewas stanting if a		considered. Include copy of this form with
LANGUAGES. Initials diagon cons	iyered. Draw ilne infough dizilon if no	it in contormance and no	t considered. Include copy of this form with
next communication to applicant,	1	: /	
TONE COMMITTEE MEDITAL APPRICATION	<u></u>		
			C. L. M. J. Die de Fe (070 4440)
<i>1</i>		•	Substitute Disclosure Form (PTO-1449)

	MIPE	·		Silect 1 01 2	_
/	Substitute Food PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No. 10/786,791	
3	by Applicant		Applicant Zhaoda Zhang et al.		
D.	(Use several s	sheets if necessary)	Filing Date February 24, 2004	Group Art Unit	

	U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
TON	AA	5,223,409	06/29/93	Ladner et al.				
101	AB	5,492,892	02/20/96	Andersen et al.				
NSA	AC	6,001,809	12/14/99	Thorsett et al.				

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
101	AD	EP 329 363	02/13/89	EPO)		
/	AE	WO 96/01644	01/25/96	PCT				
	AF	WO 96/36361	11/21/96	PCT		1		
	AG	WO 97/14804	04/24/97	PCT		•		
TO-	AH	WO 98/45331	10/15/98	PCT)		

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
TA	AI	Alavi et al., "Radiolabeled Antifibrin Antibody in the Detection of Venous Thrombosis: Preliminary Results," Radiology, 1990, 175:79-85
	AJ	Alexander et al., "Intracranial Black-Blood MR Angiography with High-Resolution 3D Fast Spin Echo," Magnetic Resonance in Medicine, 1998, 40(2):298-310
	AK	Bautovich et al., "Detection of Deep Venous Thrombi and Pulmonary Embolus with Technetium-99m-DD-3B6/22 Anti-fibrin Monoclonal Antibody Fab' Fragment," J. Nucl. Med., 1994, 35:195-202
	AL	Edelman et al., "Extracranial Carotid Arteries: Evaluation with "Black Blood" MR Angiography," Radiology, 1990, 177(1):45-50
	AM	Harker et al., "Role of Platelets and Thrombosis in Mechanisms of Acute Occlusion and Restenosis After Angioplasty," Am. J. Cardiology, 1987, 60:20B-28B
	AN	Hermans et al., "Fibrin: Structure and Interactions," Semin. Thromb. Hemost., 1982, 8:11-24
	AO	Kakkar et al., "I-Labelled Fibrinogen Test Adapted for Routine Screening for Deep-Vein Thrombosis," Lancet, 1970, 1:540-542
	Knight et al., "Fragment E ₁ Labeled with I-123 in the Detection of Venous Thrombosis," <u>Radiology</u> , 1985, 156:509-514	
	AQ	Lanza et al., "High-Frequency Ultrasonic Detection of Thrombi with A Targeted Contrast System," Ultrasound in Med. & Bio., 1997, 23(6):863-870
10	AR	Moskowitz and Budzynski, "The (DD)E Complex is Maintained by a Composite Fibrin Polymerization Site," <u>Biochemistry</u> , 1994, 33:12937-12944

Examiner Signature:		Date Considered / /
The state of the s	1	Date Considered / /
V //		1 12/x/
$I \setminus A$	1 1 1 .	1 2/5/0/-
	I Man	47/0
EXAMINER: Initials citation con	sidered Draw line through citation if no	ot in conformance and not considered. Include copy of this form with
- Vivilland Company	isidered. Dien inte ditodgit dieschi it in	of in comornance and not considered. Include copy of this form with
next communication to applican	t.	1 /

/	Sepsemble Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No. 10/786,791	
<i>(</i>	Infermation Disclosure Statement JUN 2 4 2004 B by Applicant		Applicant Zhaoda Zhang et al.		
Ž	Use several st	neets if necessary)	Filing Date February 24, 2004	Group Art Unit	

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.						
Initial	ID ID	Document					
TO	AS	Muto et al., "Initial Clinical Experience with Tc-99m P280, a Synthetic Peptide Useful for Imaging Thrombi and Pulmonary Emboli," Radiology, 1993, 189(suppl.): 303					
	AT	Nielson et al., "Cysteine Residue Periodicity is a Conserved Structural Feature of Variable Surface Proteins from Paramecium tetraurelia," J. Mol. Biol., 1991, 222:835-841					
	AU	Olexa et al., "Structure of Fragment E Species from Human Cross-Linked Fibrin," Biochemistry, 1981, 20:6139-6145					
	AV	Palabrica et al., "Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets," <u>Proc. Natl. Acad. Sci. USA</u> , 1989, 86:1036-1040					
	AW	Redenbach et al., "A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb Streptomyces coelicolor A3(2) chromosome," Mol. Microbiol., 1996, 21:77-96					
	AX	Rosebrough et al., "Thrombus Imaging: A Comparison of Radiolabeled GC4 and T2G1s Fibrin- Specific Monoclonal Antibodies," J. Nucl. Med., 1990, 31:1048-1054					
	AY	Spraggon et al., "Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin," Nature, 1997, 389:455-462					
	AZ	Thakur et al., "Indium-111 Labeled Platelets: Studies on Preparation and Evaluation of In Vitro and In Vivo Functions," Throm. Res., 1976, 9:345-357					
	AAA	GenBank Accession No. T05787					
N	ABB	GenBank Accession No. T34584					

	<u></u>
Examiner Signature	Date Considered / //
La Jane	7/3/106
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	/ / /
	Substitute Disclosure Form (PTO-1449)

Q E	Gubstit (Mboti)	ute Form	PTO-1449
0	O Tak	TO Inf	ormation b

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 13498-010003

Application No. 10/786,791

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant
Zhaoda Zhang et al.

Filing Date
February 25, 2004

Group Art Unit

THE STATE OF	U.S. Patent Documents								
Examin Initia		- 1	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
75	A	A	4,622,420	11/11/1986	Meares et al.		1		
	/ A	В	4,831,175	05/16/1989	Gansow et al.))		
	А	.c	5,099,069	03/24/1992	Gansow et al.	-			
	A	D	5,246,692	09/21/1993	Gansow et al.				
	A	Æ	6,207,858	03/27/2001	Chinn et al.				
W	A	F	6,342,598	01/29/2002	Anelli et al.)		
IN	A	.G	6,652,834	11/25/2003	Anelli et al.)		
	/ A	.H							
	A	I _							
	A	Ŋ							
	A	K							

	Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	lation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	·: No	
	AL								
	AM								
	AN								

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.					
Initiat	ID	Document				
10	AO	Restriction Requirement mailed 01/15/2004 in co-pending U.S. application serial no. 10/209,172.				
	AP	Response to Restriction Requirement mailed 02/11/2004 in co-pending U.S. application serial no. 10/209,172.				
	AQ	Supplemental Preliminary Amendment mailed 02/23/2004 in co-pending U.S. application serial no. 10/209,172.				
V	AR	Restriction Requirement mailed 01/22/2004 in co-pending U.S. application serial no. 10/209,183.				
M	AS	Preliminary Amendment and Response to Restriction Requirement mailed 02/23/2004 in co-pending U.S. application serial no. 10/209,183.				

		<i>L</i>
Examiner Signature	Date Considered /	L 1
\ \ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	0/2/	X/ρ
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not done	sidered. Include copy of this form with
next communication to applicant.		
		Substitute Disclosure Form (PTO-1440)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No. 7-86, 79/	
	closure Statement pplicant	Applicant Zhaoda Zhang et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 25, 2004	Group Art Unit	

U.S. Patent Documents								
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
RO	AA	08/875,365					12/12/97	
/	AB	4,659,839	04/21/87	Nicolotti et al.		•		
	AC	4,678,667	07/07/87	Meares et al.				
	AD	4,880,008	11/14/89	Lauffer		_		
	AE	4,897,255	01/30/90	Fritzberg et al.				
	AF	5,637,759	06/10/97	Hearst et al.		-		
A	AG	5,641,878	06/24/97	Dandliker et al.	_			
N	AH	6,517,814	02/11/03	Liu				

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	
Initial	ID	Number	Date	Patent Office	Class	Subclass	~Yes	or⊾No.
I DE	AI	0 515 313 B1	08/09/00	EPO				
	AJ	WO 93/17719	09/16/93	PCT				
	AK	WO 95/19187	07/20/95	PCT ·				
	AL	WO 96/23524	08/08/96	PCT				
	AM	WO 96/23526	08/08/96	PCT				
	AN	WO 97/13490	04/17/97	PCT			Abstr.	
V	AO	WO 01/08712	02/08/01	PCT		_		
N	AP	WO 01/09188	02/08/01	PCT				

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
A	AQ	Aime et al., "Synthesis, Characterization, and $1/T_1$ NMRD Profiles of Gadolinium(III) Complexes of Monoamide Derivatives of DOTA-like Ligands. X-ray Structure of the 10-[2-[[[2-Hydroxy-1-(hydroxymethyl)ethyl]amino]-1-[(phenylmethoxy)methyl]-2-oxo-ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic Acid-Gadolinium(III) Complex," Inorg. Chem., 1992, 31:2422-2428			
10)	AR	Aime et al., "Multinuclear and multifrequency NMR study of gadolinium(III) complexes with bisamide derivaties of ethylenedioxydiethylene-dinitrilotetraacetic acid," <u>J. Chem. Soc. Dalton Trans.</u> , 2000, pp. 3435-3440			

Examiner Signature	Date Considered /	
_ N him	2/5/06	
EXAMINER / Initials citation considered. Draw line through citation if not next communication to applicant.	in conformance and not considered. Include copy of this for	orm with
	Substitute Disclosure Form	(PTO-144

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No. 786,7	ì
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Zhaoda Zhang et al.		
		Filing Date February 25, 2004	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.		
Initial	ID	Document	
75	AS	Amedio Jr. et al., "A Practical Manufacturing Synthesis of 1-(R)-Hydroxymethyl-DTPA: An Important Intermediate in the Synthesis of MRI Contrast Agents," Synthetic Communications, 1999, 29(14):2377-2391	
	АТ	Amedio Jr. et al., "Preparation of N,N-BIS[2-[N',N'-BBIS[(Tert-Butoxycarbonyl)Methyl]-Amino]Ethyl-L-Aspartic Acid: An Intermediate in the Synthesis of MRI Contrast Agents," Synthetic Communications, 2000, 30(20):3755-3763	
	AU	Augustijns et al., "Peptidyl Dipeptidase A-Catalyzed Metabolism of Delta Sleep-Inducing Peptide in Bovine Brain Microvessel Endothelial Cells: A Cell Culture Model of the Blood Brain Barrier," <u>Biochem. Biophys. Res. Comm.</u> , 1995, 210(3):987-994	
	AV	Bakker et al., "In Vivo Application of [IIIn-DTPA-D-PHE]-Octreotide for Detection of Somatostatin Receptor-Positive Tumors in Rats," <u>Life Sciences</u> , 1991, 49:1593-1601	
	AW	Bligh et al., "Neutral Gadolinium(III) Complexes of Bulky Octadentate dtpa Derivatives as Potential Contrast Agents for Magnetic Resonance Imaging," Polyhedron, 1995, 14(4)567-569	
	AX	Bulte et al., "Dysproium-DOTA-PAMAM Dendrimers as Macromolecular T2 Contrast Agents," Invest. Radiol., 1998, 33(11):841-845	
	AY	Caravan et al., "Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications," Chem. Rev., 1999, 99:2293-2352	
	AZ	Collen et al., "Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis," J. Clin. Invest., 1983, 71:368-376	
-	AAA	Deacon et al., "Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo," J. Clin. Endocrinol., 1995, 80(3):952-957	
	ABB	Kellar et al., "Magnetic Field Dependence of Solvent Proton Relaxation by Solute Dysprosium(III) Complexes," Invest. Radiol., 1998, 33(11):835-840	
	ACC	Kojima et al., "Bioimaging of Nitric Oxide with Fluorescent Indicators Based on the Rhodamine Chromophore," Anal. Chem., 2001, 73:1967-1973	
	ADD	Kolc, "Amino Acids and Peptides. LXXXIX. Synthesis of L-4-Azalysine, D-4-Azalysine, and L-4-Analysine-[6-14C]," Coll. Czech. Chem. Commun., 1969, 34:630-634	
	AEE	Konings et al., "Gadolinium Complexation by a New DTPA-Amide Ligand. Amide Oxygen Coordination," <u>Inorg. Chem.</u> , 1990, 29:1488-1491	
	AFF	Krieter et al., "In Vivo Metabolism of Atrial Natriuretic Peptide: Identification of Plasma Metabolites and Enzymes Responsible for Their Generation," J. Pharmacol. Exp. Ther., 1989, 249(2):411-417	
	AGG	Lauffer, "Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging: Theory and Design," Chem. Rev., 1987, 87:901-927	
	АНН	Liu et al., "Labeling a Hydrazino Nicotinamide-Modified Cyclic Iib/IIIa Receptor Antagonist with 99mTc Using Aminocaroboxylates as Coligands," <u>Bioconjugate Chem.</u> , 1996, 7:63-71	
A	AII	Martin et al., "Gadolinium(III) Di- and Tetrachelates Designed for in Vivo Noncovalent Complexation with Plasma Proteins: A Novel Molecular Design for Blood Pool MRI Contrast Enhancing Agents," Bioconjugate Chem., 1995, 6:616-623	
N	AJJ	Mühler and Hochhaus, "Metabolism of Dynorphin A 1-13 in Human Blood and Plasma," Pharm. Res., 1995, 12(8):1165-1170	

	1 .		
Examiner Signature		Date Considered / /	
10	Manas	2/ B /04	
EXAMINER:/Initials citation	considered. Draw line through citation if no	t in conformance and not considered. Incl	ude copy of this form with
next communication to applic	cant.	/ /	••
		Cubatituta	Dinelegues Form (DTO 4440)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Zhaoda Zhang et al.	
		Filing Date February 25, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
(A)	AKK	Mühler et al., "Interspecies comparison of in vitro plasma degradation of dynorphin A 1-13," Pharmazie, 1996, 51(8):581-585		
	ALL	Muller et al., "Physicochemical Characterization of MS-325, a New Gadolinium Complex, by Multinuclear Relaxometry," Eur. J. Inorg. Chem., 1999, pp. 1949-1955		
	AMM	Mühler et al., "Assessment of Complex Peptide Degradation Pathways via Structured Multicompartmental Modeling Approaches: The Metabolisn of Dynorphin A1-13 and Related Fragments in Human Plasma," J. Pharm. Sci., 1999, 88(9):938-944		
	ANN	Murphey et al., "Metabolism of Bradykinin in Vivo in Humans: Identification of BK1-5 as a Stable Plasma Peptide Metabolite," J. Pharmacol. Exp. Ther., 2000, 294:263-269		
	AOO	Murru et al., "Luminescence Behaviour of Stable Europium and Terbium Complexes of Tetraaza Phosphinates: Efficient Through-space Energy Transfer from Phenyl to Terbium," J. Chem. Soc. Chem. Commun., 1993, pp. 1116-1118		
	APP	Muto et al., "Detecting Deep Venous Thrombosis with Technetium-99m-Labeled Synthetic Peptide P280," J. Nucl. Med., 1995, 36(8):1384-1391		
	AQQ	Oefner et al., "High-Resolution Liquid Chromatography of Fluorescent Dye-Labeled Nucleic Acids," Analytical Biochem., 1994, 223:39-46		
	ARR	Pearson et al., "Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies," J. Med. Chem., 1996, 39:1361-1371		
	ASS	Powell et al. "Peptide Stability in Drug Development. II. Effect of Single Amino Acid Substitution and Glycosylation on Peptide Reactivity in Human Serum," Pharm. Res., 1993, 10(9):1268-1273		
	ATT	Powell et al., "Structural and Dynamic Parameters Obtained from ¹⁷ O NMR, EPR, and NMRD Studies of Monomeric and Dimeric Gd ³⁺ Complexes of Interest in Magnetic Resonance Imaging: An Integrated and Theoretically Self-Consistent Approach," J. Am. Chem. Soc., 1996, 118:9333-9346		
	AUU	Ramachandran et al., "New Multimeric Magnetic Resonance Imaging Agents," Invest. Radiol., 1998, 33(11):779-797		
	AVV	Reubi et al., "Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo," <u>Eur. J. Nucl. Med.</u> , 1998, 25(5):481-490		
	AWW	Solomon et al., "Focal Infection Imaging Using an In-111 Labeled Antagonist Chemotactic Peptide," J. Nucl. Med., 1994, 35(5):45P, Abstract No. 172		
	AXX	Stall et al., "Rearrangement and expression of endogenous immunoglobulin genes occur in many murine B cells expressing transgenic membrane IgM," <u>Proc. Natl. Acad. Sci. USA</u> , 1988, 85:3546-3550		
	AYY	Toth et al., "The Role of Water Exchange in Attaining Maximum Relaxivities for Dendrimeric MRI Contrast Agents," Chem. Eur. J., 1996, 2(12):1607-1615		
V	AZZ	Tóth et al. "Tuning water-exchange rates on (carboxymethyl)iminobis-(ethylenenitrilo)tetraacetate (dtpa)-type gadolinium(III) complexes," J. Chem. Soc., Dalton Trans., 1997, pp. 1587-1594		
TO	AAAA	Tóth et al., "Direct assessment of water exchange on a Gd(III) chelate bound to a protein," <u>J. Biol. Inorg. Chem.</u> , 1998, 3:606-613		

Examiner Signature	Date Considered //_
	~ 12.10
11) 1000	2/20/0/20
EXAMINER: Initials citation considered. Draw line through citation if no	ot in conformance/and not considered. Include copy of this form with
next communication to applicant.	/,
	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13498-010003	Application No. [0] 78(e,79]
(Use several sheets if necessary)		Applicant Zhaoda Zhang et al.	
		Filing Date February 25, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.	_	
Initial	ID	Document	
7	ABBB	Uggeri et al., "Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and Characterization of the Ligand BOPTA and Its Ln(III) Complexes (Ln = Gd, La, Lu). X-ray Structure of Disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)]gadolinate(2-) in a Mixture with Its Enantiomer," Inorg. Chem., 1995, 34:633-642	
	ACCC	Weinmann et al. "A New Lipophilic Gadolinium Chelate as a Tissue-Specific Contrast Medium for MRI," Magn. Reson. Med., 1991, 22:233-237	
X	ADDD	Wettergren et al. "Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans," Reg. Peptides, 1998, 77:83-87	
N	AEEE	Zhao et al., "Oxidation of Primary Alcohols to Carboxylic Acids with Sodium Chlorite Catalyzed by TEMPO and Bleach," J. Org. Chem., 1999, 64:2564-2566	

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)